Skip to main content
Premium Trial:

Request an Annual Quote

Gyros, Fluidigm, MDS Metro Laboratory Services, Genome British Columbia, University of Victoria, Oxford GlycoSciences, GWC, Hybrigenics, Institut Curie, Europroteome, Aventis, Frost & Sullivan

Premium

Gyros Licenses Technology to Fluidigm

Gyros of Uppsala, Sweden, has licensed “some of its” patented microfluidics technology to Fluidigm of South San Francisco. The licensing deal covers US patent 5,376,252 as well as corresponding worldwide patents. The patent is entitled “Microfluidic structure and process for its manufacture.”

 

MDS, Genome BC, U. Victoria Establish Proteomics Facility On VAncouver Island

MDS Metro Laboratory Services, Genome British Columbia, and the University of Victoria announced last week they would establish a proteomics research facility in the Vancouver Island Technology Park. The facility, which was formerly located at the University of Victoria, will find a new home at the 17,000-square foot space, which is next to MDS Metro. It includes several mass spectrometers, as well as protein separation, analysis, and processing systems. Researchers at this center will be able to collaborate with MDS Metro scientists on developing proteomics-based lab tests. MDS Metro is a laboratory testing subsidiary of MDS and employs 450 employees.

 

OGS Withdraws Recommendations to Shareholders on CAT Merger

Oxford GlycoSciences’ board withdrew its previous recommendation to shareholders advising a merger with Cambridge Antibody Technology last week, but continued to advise against a rival cash bid from Celltech. The board said its withdrawl of the recommendation came under advisement by Goldman Sachs, “given the current difference in value of the CAT merger relative to the Celltech Offer,” but added that it “intends to pursue further discussions with CAT regarding a potential revised proposal and also to seek or consider offers from other potentially interested third parties.”

 

GWC to Supply Technology to Toyobo

University of Wisconsin spinout GWC instruments has signed a contract to supply surface plasmon resonance instruments and software to Japanese materials giant Toyobo, a University of Wisconsin news service said last week. Under the three-year agreement, Toyobo will distribute GWC’s SPR imaging systems around the world to microarray researchers, along with its biomolecular array spotting and surface chemistry system. The three-person company said the agreement would bring “several hundred thousand dollars to GWC in the first year.” GWC’s SPR system is designed to enable label-free detection of numerous biomolecular samples at once, whereas other SPR systems can only measure a few samples at a time, according to the company.

 

Hybrigenics, Institut Curie Get €2.4 Million

Earlier this month, the French government awarded Hybrigenics and the Institut Curie €2.4 million ($2.6 million) for their joint proteomics research. The financing, which will span three years, includes €1.4 million ($1.5 million) that Hybrigenics will receive as payment for supplying its yeast two hybrid protein-protein interaction technology in an 18-month-old collaboration with the Institut Curie. The institute will receive €1 million (about $1.1 million), half of which will pay for nine postdoctoral grants, the other half of which will go toward the operating expenses of the laboratory that the institute jointly operates with Hybrigenics in Paris. In this newly-funded stage of the collaboration, Institut Curie researchers are using protein interaction maps to examine biological pathways in cancer.

 

Europroteome, Immunotope Work More Closely

Europroteome of Henningsdorf, Germany, and Immunotope of Richboro, Pennsylvania, said this month they will broaden their collaboration. Following last year’s pilot study, the companies will aim to identify colon cancer-specific MHC class I- and II-associated peptide antigens as targets, and their related proteins as diagnostic markers. Europroteome will develop and commercialize any products resulting from the collaboration.

 

Aventis Buys Zyomyx’s Protein Biochip System

Zyomyx said this month that Aventis will purchase its protein profiling biochip system. The platform currently runs the company’s human cytokine biochip, which can profile 30 cytokines. Aventis will use the system in its research and development programs in inflammation, according to Zyomyx.

 

Frost & Sullivan Predicts Proteomics Sample Prep Market Will Grow to $367.7M

A new analysis by Frost & Sullivan predicts that the worldwide proteomics sample preparation market will grow from $57.8 million in 2000 to $367.7 million by 2009. “Tool providers that address this challenge through custom-made solutions for proteomics researchers can reap great profits,” the company stated, adding that alliances are likely.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.